Answers are grounded in this paper and cite their sources.
Background Inborn errors of immunity (IEI) are individually rare but collectively affect an estimated 30,000 Canadians. Their genetic and clinical heterogeneity, combined with limited disease-specific data, presents challenges in diagnosis, management, and evaluation of treatment outcomes. A national registry with standardized longitudinal data collection is needed to better characterize disease manifestations, support clinical research, inform healthcare planning, and improve care for individuals with IEI across Canada. Methods A national steering committee comprising 13 clinician-researchers from 3 adult and 8 pediatric centres across 9 Canadian provinces established the Canadian Inborn Errors of Immunity National Registry (CIEINR). Development was informed by an environmental scan of existing rare disease registries and consultations with bioinformatics experts and patient representatives. A multidomain electronic case report form (eCRF) was developed using Research Electronic Data Capture (REDCap), hosted at the University of Calgary, to systematically collect demographic, genetic, clinical, treatment, and outcome data. Results Between 2021 and 2025, the CIEINR governance framework, research protocols, and standardized data model were developed and peer-reviewed. The eCRF incorporates ontology-based medical terminologies to facilitate standardized characterization of clinical manifestations, data harmonization, and interoperability. The RareLink framework was adapted to support internationally standardized data linkage and generation of Global Alliance for Genomics and Health (GA4GH) Phenopackets, enabling structured, machine-readable representation of clinical and genomic information. Registry governance documents, policies, and data models are shared through an open-access GitHub repository to promote transparency, reproducibility, and collaboration. Conclusions The innovative CIEINR provides a national infrastructure for standardized, longitudinal collection of diagnosis, disease course, treatment, outcomes, and genomic data ac across the spectrum of IEI. High-quality, standardized, machine-readable, and interoperable data will enable Phenopacket analysis, support research on new therapies, and foster international collaboration. By openly sharing its governance framework, policies, and data model, CIEINR establishes a reproducible approach to rare disease registry development while advancing evidence-based clinical care, patient advocacy, and healthcare policy.
No takes yet. Share an insight, caveat, or question.
Kalashnikova et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: